scholarly journals Differential expression of 37 selected genes in hormone‐refractory prostate cancer using quantitative taqman real‐time RT‐PCR

2004 ◽  
Vol 114 (2) ◽  
pp. 174-181 ◽  
Author(s):  
Gaëlle Fromont ◽  
Laurent Chene ◽  
Michel Vidaud ◽  
Guy Vallancien ◽  
Philippe Mangin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real Time ◽  
Differential Expression ◽  
Hormone Refractory Prostate Cancer ◽  
Rt Pcr ◽  
Hormone Refractory

Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Metastatic Prostate Cancer: A Nested Study Within CALGB 9583

2003 ◽  
Vol 21 (3) ◽  
pp. 490-495 ◽  
Author(s):  
Susan Halabi ◽  
Eric J. Small ◽  
Daniel F. Hayes ◽  
Nicholas J. Vogelzang ◽  
Philip W. Kantoff
Keyword(s):  
Prostate Cancer ◽  
Polymerase Chain Reaction ◽  
Prognostic Factor ◽  
Specific Antigen ◽  
Risk Groups ◽  
Hormone Refractory Prostate Cancer ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Hormone Refractory

Purpose: To determine whether reverse transcriptase polymerase chain reaction (RT-PCR) to detect circulating prostate-specific antigen (PSA)-positive cells is a prognostic factor for survival in hormone refractory prostate cancer and to validate the prognostic importance of this test in relation to other known prognostic factors. Patients and Methods: A single centralized laboratory received and analyzed whole blood for RT-PCR for PSA for a subset of patients enrolled on two Cancer and Leukemia Group B (CALGB) randomized trials (CALGB 9583 and CALGB 9480). Using 9583, a prognostic model was developed and an independent data set (CALGB 9480) was used to validate the fitted model. Results: Of 162 patients in 9583, 91 (56%) patients were negative for RT-PCR for PSA and 71 (44%) patients were positive. The median survival time was 21 months (95% confidence interval [CI], 18 to 27 months) for RT-PCR-negative patients compared with 11 months (95% CI, 8 to 15 months) for RT-PCR-positive patients (P ≤ .001). In multivariable analysis, the hazard ratio (HR) for death was 1.7 (95% CI, 1.2 to 2.4; P = .006) for positive RT-PCR patients compared with negative RT-PCR patients. A fitted model that incorporated RT-PCR for PSA and other factors was used to classify patients from 9480 into one of two risk groups: low or high. We observed good agreement between the observed and predicted survival probabilities for the two risk groups. Conclusion: RT-PCR to detect PSA-positive circulating cells is confirmed to be a significant prognostic factor of survival in patients with hormone refractory prostate cancer. This model could be used to stratify patients in randomized phase III trials.

Prognostic Significance of Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen in Men With Hormone-Refractory Prostate Cancer

2001 ◽  
Vol 19 (12) ◽  
pp. 3025-3028 ◽  
Author(s):  
Philip W. Kantoff ◽  
Susan Halabi ◽  
Deborah A. Farmer ◽  
Daniel F. Hayes ◽  
Nicholas A. Vogelzang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Polymerase Chain Reaction ◽  
Prostate Specific Antigen ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Hormone Refractory Prostate Cancer ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
Hormone Refractory

PURPOSE: To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS: Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR. RESULTS: RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival for those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P = .004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information. CONCLUSION: RT-PCR for PSA predicts survival duration in a population of men with HRPC.

604: A Phase I Trial of Vaccination of Personalized Peptides for HLA-A2/A24 Positive Patients with Hormone-Refractory Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 202-202
Author(s):  
Hirotsugu Uemura ◽  
Motoyoshi Tanaka ◽  
Shigeya Uejima ◽  
Takafumi Minami ◽  
Kiyohide Fujimoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

829: PSA-Flare up in Docetaxel Therapy of Hormone-Refractory Prostate cancer (HRPCA): Incidence and Clinical Impact?

2005 ◽  
Vol 173 (4S) ◽  
pp. 225-225
Author(s):  
Peter Olbert ◽  
Andres J. Schrader ◽  
Axel Hegele ◽  
Zoltan Varga ◽  
Axel Heidenreich ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Impact ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

531: Quantitative Real-Time RT-PCR for AMACR Distinguishes Prostate Cancer with High Specificity From Benign Lesions

2005 ◽  
Vol 173 (4S) ◽  
pp. 145-145 ◽  
Author(s):  
Martin Schostak ◽  
Hans Krause ◽  
Jens Köllermann ◽  
Mark Schrader ◽  
Bernd Straub ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real Time ◽  
High Specificity ◽  
Rt Pcr ◽  
Benign Lesions

1504: Molecular Diagnosis and Staging of Prostate Cancer Using Clusterin in Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)

2006 ◽  
Vol 175 (4S) ◽  
pp. 485-486
Author(s):  
Sabarinath B. Nair ◽  
Christodoulos Pipinikas ◽  
Roger Kirby ◽  
Nick Carter ◽  
Christiane Fenske
Keyword(s):  
Prostate Cancer ◽  
Polymerase Chain Reaction ◽  
Real Time ◽  
Molecular Diagnosis ◽  
Reverse Transcription ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Polymerase Chain
Sign in / Sign up

Export Citation Format

Share Document